1. Herpes Simplex Virus Type 2 Serostatus Is Not Associated with Inflammatory or Metabolic Markers in Antiretroviral Therapy-Treated HIV.

    AIDS Research and Human Retroviruses 31(3):276 (2015) PMID 25399537

    Systemic inflammation and immune activation may persist in HIV-infected persons on suppressive combination antiretroviral therapy (cART) and contribute to adverse health outcomes. We compared markers of immune activation, inflammation, and abnormal glucose and lipid metabolism in HIV-infected ad...
  2. Herpes Simplex Virus Type 2 Serostatus Is Not Associated with Inflammatory or Metabolic Markers in Antiretroviral Therapy-Treated HIV.

    AIDS Research and Human Retroviruses 31(3):276 (2015) PMID 25399537 PMCID PMC4348084

    Systemic inflammation and immune activation may persist in HIV-infected persons on suppressive combination antiretroviral therapy (cART) and contribute to adverse health outcomes. We compared markers of immune activation, inflammation, and abnormal glucose and lipid metabolism in HIV-infected ad...
  3. Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV.

    AIDS Research and Human Retroviruses 31(3):276 (2015) PMID 25399537 PMCID PMC4348084

    Systemic inflammation and immune activation may persist in HIV-infected persons on suppressive combination antiretroviral therapy (cART) and contribute to adverse health outcomes. We compared markers of immune activation, inflammation, and abnormal glucose and lipid metabolism in HIV-infected ad...
  4. Herpes Simplex Virus Type 2 Serostatus Is Not Associated with Inflammatory or Metabolic Markers in Antiretroviral Therapy-Treated HIV.

    AIDS Research and Human Retroviruses 31(3):276 (2015) PMID 25399537 PMCID PMC4348084

    Systemic inflammation and immune activation may persist in HIV-infected persons on suppressive combination antiretroviral therapy (cART) and contribute to adverse health outcomes. We compared markers of immune activation, inflammation, and abnormal glucose and lipid metabolism in HIV-infected ad...
  5. HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction.

    Journal of Infectious Diseases 211(1):10 (2015) PMID 25030058 PMCID PMC4264589

    Protease inhibitor (PI)-based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestational-age...
  6. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.

    Journal of Infectious Diseases 211(1):10 (2015) PMID 25030058 PMCID PMC4264589

    Protease inhibitor (PI)-based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestational-age...
  7. HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction.

    Journal of Infectious Diseases 211(1):10 (2015) PMID 25030058

    Protease inhibitor (PI)-based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestational-age...
  8. HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction.

    Journal of Infectious Diseases 211(1):10 (2015) PMID 25030058 PMCID PMC4264589

    Protease inhibitor (PI)-based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestational-age...
  9. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.

    Journal of Infectious Diseases 211(1):10 (2015) PMID 25030058 PMCID PMC4264589

    Protease inhibitor (PI)-based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestational-age...
  10. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance.

    Clinical Infectious Diseases 59(7):944 (2014) PMID 24973312

    Estimating the risk of antibiotic resistance is important in selecting empiric antibiotics. We asked how the timing, number of courses, and duration of antibiotic therapy in the previous 3 months affected antibiotic resistance in isolates causing invasive pneumococcal disease (IPD). We conducted...
  11. Self-Reported Preconception Care of HIV-Positive Women of Reproductive Potential: A Retrospective Study.

    Journal of the International Association of Pr... 13(5):424 (2014) PMID 23918921

    We determined the proportion and correlates of self-reported pregnancy planning discussions (that is preconception counseling) that HIV-positive women reported to their family physicians (FPs), HIV specialists, and obstetrician/gynecologists (OB/Gyns). In a cross-sectional substudy, HIV-positive...
  12. In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents.

    Pharmaceutical Research 31(9):2404 (2014) PMID 24595498

    The objectives of this study were to evaluate the effects of intestinal lumen pH, food intake, and acid-reducing agents on the intestinal permeability of atazanavir, an HIV-1 protease inhibitor. Atazanavir permeability across Caco-2 cell monolayers (P app) and in situ steady-state permeability a...
  13. Raltegravir as antiretroviral therapy in HIV/AIDS.

    Expert Opinion on Pharmacotherapy 15(3):395 (2014) PMID 24304203

    HIV, a major cause of morbidity and mortality worldwide has been transformed by antiretroviral (ARV) therapy into a manageable condition. Drug resistance, tolerability and drug interactions remain major concerns when choosing ARV therapy. Raltegravir , the first integrase inhibitor in the armame...
  14. Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.

    Mediators of Inflammation 2014:803095 (2014) PMID 24991090 PMCID PMC4058804

    Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects. We assessed urinary F2-isoprostanes (F2-...
  15. Antiretroviral therapy is not associated with reduced herpes simplex virus shedding in HIV coinfected adults: an observational cohort study.

    BMJ Open 4(1):e004210 (2014) PMID 24464523 PMCID PMC3902380

    Herpes simplex virus types 1 and 2 (HSV-1/2) may have adverse consequences on HIV type 1 infection. We quantified the frequency of HSV reactivations in highly active antiretroviral therapy (HAART)-treated adults with HIV, and compared it with that in HAART-naïve patients. 2 academic hospital sit...
  16. The importance of motherhood in HIV-positive women of reproductive age in Ontario, Canada.

    AIDS Care 26(6):777 (2014) PMID 24206065

    Motherhood is personally, culturally, and historically rooted. Recent publications have focused on medical issues related to pregnancy and HIV, with attention on fetal well-being. There is limited literature on the importance of motherhood for HIV-positive women. Our study's purpose was to inves...
  17. Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.

    Mediators of Inflammation 2014:803095 (2014) PMID 24991090 PMCID PMC4058804

    Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects. We assessed urinary F2-isoprostanes (F2-...
  18. Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.

    Mediators of Inflammation 2014:803095 (2014) PMID 24991090 PMCID PMC4058804

    Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects. We assessed urinary F2-isoprostanes (F2-...
  19. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

    New England Journal of Medicine 369(19):1807 (2013) PMID 24195548

    Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was recently approved in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Dolutegravir, in combination with abacavir-lamivudine, ...
  20. Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection.

    Clinical Infectious Diseases 57(3):448 (2013) PMID 23572481

    Herpes simplex virus type 2 (HSV-2) reactivations are associated with increased HIV load, but whether HSV-2 coinfection accelerates HIV disease is unclear. We compared rates of CD4 count decline according to HSV-2 status in untreated HIV-infected adults. HIV-infected patients with a past period ...